Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
American chemical industry news
27 February 2026
FDA Approves Novo Nordisk's Sogroya for New Pediatric Uses
Sogroya, a once-weekly growth hormone, is now approved for children with ISS, SGA, or NS, offering an alternative to daily injections and expanding treatment options.
27 February 2026
Merck's KEYTRUDA and Padcev Cut Event-Free Survival Risk by 47% and Mortality by 35% in Cisplatin-Eligible Bladder Cancer Patients
KEYTRUDA plus Padcev improves survival and reduces recurrence in muscle-invasive bladder cancer, showing potential as a new standard for cisplatin-eligible patients.
27 February 2026
Merck's KEYTRUDA Plus Paclitaxel Boosts Survival in Platinum-Resistant Ovarian Cancer
KEYTRUDA plus paclitaxel improves overall survival in platinum-resistant ovarian cancer, regardless of PD-L1 status, as shown in the KEYNOTE-B96 trial.
27 February 2026
Lilly's Olumiant Gains CHMP Nod for Adolescent Alopecia Areata in EU
CHMP backs Olumiant for severe alopecia areata in adolescents, based on Phase 3 study showing 42% achieved 80% scalp hair coverage at 36 weeks. Awaiting European Commission decision.
27 February 2026
CABB Group Sells Jayhawk Fine Chemicals to Anupam Rasayan
CABB shifts focus to Pharma and Life Science, selling Jayhawk for $150M. Anupam Rasayan aims to expand its US presence and performance materials business.
27 February 2026
Ercros Reports EUR 8M EBITDA, EUR 54M Loss
Weak demand, high energy costs, and competition impact results. Cost reduction plan on track. Financial debt reduced. Takeover bid rejected. Demand recovery expected in late 2026.
How does the American chemical industry perform?
Find out with
chemXplore Analytics
Learn more
26 February 2026
thyssenkrupp Automotive Body Solutions Joins IPAI for Smart Manufacturing Innovation
The company joins IPAI to integrate AI in manufacturing, enhancing robotics and expanding globally, with a focus on intelligent production and quality monitoring.
26 February 2026
MOL Accuses JANAF of Legal Violations Over Russian Oil Transit
MOL demands JANAF allow unsanctioned Russian oil via sea, citing EU/US rules. Non-compliance may lead to legal action and claims for damages.
26 February 2026
PureCycle Technologies Q4 2025 Results and Update
Record production, revenue growth, expansion in Thailand and Belgium, and leadership changes. Gen-2 design shows cost efficiency. Financials stable with ongoing projects and debt management.
26 February 2026
TotalEnergies to Export 2 Mtpa LNG from Alaska Project for 20 Years
The Alaska LNG project, with a 20 Mtpa capacity, aims to supply Asia, enhancing energy security and transpacific ties. It has strong U.S. support and offers logistical advantages.
26 February 2026
FDA Approves Boehringer Ingelheim's HERNEXEOS for HER2-Mutant NSCLC
HERNEXEOS gains FDA approval for HER2-mutant NSCLC, showing a 76% response rate in trials. Further confirmation required for continued approval.
26 February 2026
BASF Introduces Biomass Balance Autofroth Foam for North American Market
BMB Autofroth foam cuts carbon emissions by 18-20%, offers a drop-in solution for sustainability without process changes, and suits various applications.
26 February 2026
Lilly's Orforglipron Outperforms Semaglutide in Diabetes Trial
Orforglipron 36 mg reduced A1C by 2.2% and weight by 9.2%, surpassing semaglutide in a 52-week trial with 1,698 participants. Results published in The Lancet.
26 February 2026
Veolia 2025 Results Overview
Strong 2025 results with growth in international markets, early ROCE target achievement, key acquisitions, increased dividend, and positive 2026 outlook.
26 February 2026
Covestro Meets 2025 Guidance Amid Challenges
Sales and EBITDA fell in 2025. Strategic moves and partnerships aim to boost growth. 2026 outlook: stable EBITDA, improved cash flow, and reduced emissions.
26 February 2026
Technip Energies 2025 Financial Results
Strong 2025 results with revenue and EBITDA growth, dividend increase, share buyback, and strategic acquisition. Positive outlook for 2026 with robust backlog and sustainability focus.
26 February 2026
2025 Results: Arkema Performance Summary
Strong cash flow and EBITDA, sales growth in key markets, successful capacity expansions, and sustainability progress. Dividend stable; 2026 targets slight EBITDA growth amid weak demand.
25 February 2026
Merck Animal Health's NUMELVI: FDA-Approved JAK Inhibitor for Canine Allergic Dermatitis
FDA approves NUMELVI for dogs 6+ months, a JAK inhibitor for allergic dermatitis, offering rapid itch relief and easy dosing. Available spring 2026.
25 February 2026
Merck Presents Phase 3 Trial Results for HIV-1 Treatment DOR/ISL at CROI 2026
DOR/ISL shows non-inferiority and similar safety to BIC/FTC/TAF in HIV-1 treatment-naïve adults and maintains suppression in those switching from other therapies.
25 February 2026
BASF SE Nominates Mark Garrett for Supervisory Board Election 2026
Mark Garrett, former CEO and board member, is nominated to succeed Liming Chen on BASF's Supervisory Board, with the election set for April 2026.
25 February 2026
Novo Nordisk and Vivtex Collaborate on Oral Medicines for Obesity and Diabetes
The partnership aims to develop oral biologics for obesity and diabetes, leveraging Vivtex's technology for better bioavailability and Novo Nordisk's expertise in global development and commercialization.
25 February 2026
Clariant Gains EU Approval for Rice Bran Wax in Food-Contact Plastics
EU approval allows rice bran wax additives in PET, PLA, and PVC for food-contact, offering a sustainable alternative to montan wax with lower carbon footprint and supply chain benefits.
25 February 2026
Vopak Announces Record 2025 Results and EUR 1.7 Billion Shareholder Program
Net profit rose 61% to EUR 604M. Operating cash flow hit EUR 823M. EUR 4B investment by 2030 planned. EUR 1.1B in growth projects underway. Energy transition projects worth EUR 200M in progress.
24 February 2026
Johnson & Johnson Seeks FDA Approval for IMAAVY® to Treat wAIHA
IMAAVY® targets wAIHA by blocking FcRn, reducing IgG. Phase 2/3 study shows improved hemoglobin and fatigue.
24 February 2026
Iberdrola France Sells Onshore Portfolio to Technique Solaire
The sale includes 118 MW of wind capacity and 639 MW pipeline. It's part of a strategy to focus on core businesses and key markets like the US and UK. Fifth transaction this year.
23 February 2026
LyondellBasell Updates 2030 Sustainability Goals
LYB revises 2030 goals: 32% emissions cut, 800,000 tons recycled polymers. Focus on circular, low-carbon growth, capital discipline, and sustainability.
23 February 2026
Merck Restructures Human Health Division for Enhanced Portfolio Execution
Merck forms Oncology and Specialty units, appoints new leaders, and aims to boost commercial success and pipeline execution.
23 February 2026
Sasol Advances Strategic Goals, Meets CMD Targets
Sasol reports stable turnover, improved production, and reduced costs. Despite lower earnings, free cash flow rose, supported by strategic initiatives and disciplined management.
23 February 2026
Novo Nordisk: CagriSema Shows 23% Weight Loss in Trial, Misses Primary Endpoint
CagriSema achieved 23% weight loss in 84 weeks but didn't match tirzepatide. Further trials will explore higher doses. Safe profile with mild gastrointestinal effects.
23 February 2026
Sasol Advances Strategic Goals, Meets CMD Targets
Despite a challenging macro environment, Sasol improved production, managed costs, and increased free cash flow, while advancing its Grow and Transform strategy.
Next →
